Medicinal Chemistry of Drugs Affecting the Nervous System:
The primary objective of this 4-volume book series is to educate PharmD students on the subject of medicinal chemistry. The book set serves as a reference guide to pharmacists on aspects of the chemical basis of drug action. Medicinal Chemistry of Drugs Affecting the Nervous System is the second vol...
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Singapore :
Bentham Science Publishers,
2020.
|
| Schriftenreihe: | Medicinal Chemistry for Pharmacy Students Ser.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | The primary objective of this 4-volume book series is to educate PharmD students on the subject of medicinal chemistry. The book set serves as a reference guide to pharmacists on aspects of the chemical basis of drug action. Medicinal Chemistry of Drugs Affecting the Nervous System is the second volume of the series and it presents 8 chapters focusing on a comprehensive account of drugs affecting the nervous system. The volume informs readers about the medicinal chemistry of relevant drugs, which includes the mechanism of drug action, detail structure activity relationships and metabolism as w. |
| Beschreibung: | Description based upon print version of record. |
| Beschreibung: | 1 online resource (406 p.). |
| ISBN: | 9811454078 9789811454073 |
Internformat
MARC
| LEADER | 00000cam a2200000Mu 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-on1202480440 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 201031s2020 si o ||| 0 eng d | ||
| 040 | |a EBLCP |b eng |c EBLCP |d EBLCP |d YDX |d UKAHL |d N$T |d OCLCF |d OCLCO |d K6U |d OCLCQ |d OCLCO |d OCLCL | ||
| 066 | |c (S | ||
| 019 | |a 1200197704 |a 1202449622 | ||
| 020 | |a 9811454078 | ||
| 020 | |a 9789811454073 |q (electronic bk.) | ||
| 035 | |a (OCoLC)1202480440 |z (OCoLC)1200197704 |z (OCoLC)1202449622 | ||
| 050 | 4 | |a RM315 | |
| 082 | 7 | |a 615.78 |2 23 | |
| 049 | |a MAIN | ||
| 245 | 0 | 0 | |a Medicinal Chemistry of Drugs Affecting the Nervous System |h [electronic resource]. |
| 260 | |a Singapore : |b Bentham Science Publishers, |c 2020. | ||
| 300 | |a 1 online resource (406 p.). | ||
| 490 | 1 | |a Medicinal Chemistry for Pharmacy Students Ser. | |
| 500 | |a Description based upon print version of record. | ||
| 505 | 0 | |a Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- Drugs Affecting the Cholinergic System -- Cory R. Theberge1, Kim Lindsey-Goodrich2 and Ashok E. Philip3,* -- HISTORICAL PERSPECTIVES -- INTRODUCTORY CONCEPTS -- Choline and Acetylcholine -- Acetylcholine and Neurotransmission -- Cholinergic Neurochemistry: ACh Biosynthesis, Storage, Release, and Metabolism -- Cholinergic Receptors -- Muscarinic and Nicotinic Subtypes -- Clinical Use of Acetylcholine -- MUSCARINIC RECEPTOR AGONISTS -- MUSCARINIC RECEPTOR ANTAGONISTS (ANTICHOLINERGICS) | |
| 505 | 8 | |a Donepezil (Aricept®) -- Pharmacokinetics -- Side effects/Drug Interactions -- Rivastigmine (Exelon®) 2000, Oral -- 2008, Patch -- Pharmacokinetics -- Side effects/Drug Interactions -- Galantamine (Razadyne®) 2001 -- Pharmacokinetics -- Side effects/Drug-interactions -- NMDA Receptor Antagonist: Memantine (Namenda®) 2003 -- Pharmacokinetics -- Side effects/Drug interactions -- Place in Therapy -- CASE STUDY -- What therapeutic modifications would you make at this time and why? -- Drug Discovery Case Study -- The Quaternary Advantage -- Ipratropium and the Kinetic Selectivity of Tiotropium | |
| 505 | 8 | |a STUDENT SELF STUDY GUIDE -- PRACTICE QUESTIONS -- NOTES -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Drugs Affecting Adrenergic System -- M. O. Faruk1,* and Les Ramos2 -- HISTORICAL BACKGROUND -- THE INTRODUCTORY CONCEPTS -- Adrenergic Neurotransmitters -- Adrenergic Receptors (ARs) -- DRUGS AFFECTING ADRENERGIC SYSTEM: STRUCTURES, ACTIVITY, METABOLISM AND RELATED THERAPEUTIC CONSIDERATIONS -- The Antiadrenergics Affecting Synthesis, Storage, or Release of NE (Fig. 7) -- Metyrosine -- Reserpine -- Mechanism of Action -- Pharmacokinetics | |
| 520 | |a The primary objective of this 4-volume book series is to educate PharmD students on the subject of medicinal chemistry. The book set serves as a reference guide to pharmacists on aspects of the chemical basis of drug action. Medicinal Chemistry of Drugs Affecting the Nervous System is the second volume of the series and it presents 8 chapters focusing on a comprehensive account of drugs affecting the nervous system. The volume informs readers about the medicinal chemistry of relevant drugs, which includes the mechanism of drug action, detail structure activity relationships and metabolism as w. | ||
| 650 | 0 | |a Neuropharmacology. |0 http://id.loc.gov/authorities/subjects/sh85091157 | |
| 650 | 0 | |a Autonomic nervous system |x Effect of drugs on. | |
| 650 | 0 | |a Central nervous system |x Effect of drugs on. | |
| 650 | 0 | |a Pharmaceutical chemistry. |0 http://id.loc.gov/authorities/subjects/sh85023026 | |
| 650 | 2 | |a Neuropharmacology |0 https://id.nlm.nih.gov/mesh/D009480 | |
| 650 | 2 | |a Chemistry, Pharmaceutical |0 https://id.nlm.nih.gov/mesh/D002626 | |
| 650 | 6 | |a Neuropharmacologie. | |
| 650 | 6 | |a Système nerveux autonome |x Effets des médicaments sur. | |
| 650 | 6 | |a Système nerveux central |x Effets des médicaments sur. | |
| 650 | 6 | |a Chimie pharmaceutique. | |
| 650 | 7 | |a Central nervous system |x Effect of drugs on |2 fast | |
| 650 | 7 | |a Neuropharmacology |2 fast | |
| 650 | 7 | |a Pharmaceutical chemistry |2 fast | |
| 700 | 1 | |a Faruk, M. O. | |
| 700 | 1 | |a Philip, Ashok E. | |
| 758 | |i has work: |a Medicinal chemistry of drugs affecting the nervous system (Text) |1 https://id.oclc.org/worldcat/entity/E39PCYjJk8cCWMXTfpjt7C9KdP |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |a Faruk, M. O. |t Medicinal Chemistry of Drugs Affecting the Nervous System |d Singapore : Bentham Science Publishers,c2020 |z 9789811454059 |
| 830 | 0 | |a Medicinal Chemistry for Pharmacy Students Ser. | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2649039 |3 Volltext |
| 880 | |6 500-00/(S |a Therapeutic Evaluation of the Imidazoline α Adrenergic Agonists | ||
| 880 | 8 | |6 505-00/(S |a Guanethidine and Guanadrel -- Direct-Acting Sympathomimetic Agents -- The General Mechanism and SAR of β-Phenylethylamine Derivatives (Direct and Indirect Acting Agonists) -- Sar 1 -- Sar 2 -- Sar 3 -- Sar 4 -- Sar 5 -- Sar 6 -- Sar 7 -- Sar 8 -- Sar 9 -- Therapeutic Evaluation of the β-Phenylethylamine Direct Acting Adrenergic Agonists -- β2 Adrenergic Agonist and Cardiac Function -- Long Acting β2-Adrenoceptor Agonists (LABAs) -- β3 Adrenergic Receptor Agonist -- The General SAR of Imidazolines (α Adrenergic Agonist and Antagonists) -- Sar 1 -- Sar 2 -- Sar 3 | |
| 880 | 8 | |6 505-00/(S |a Acetylcholinesterase (AChE) Inhibitors -- Reversible Noncovalent Inhibitors -- Reversible Covalent Inhibitors -- Irreversible Covalent Inhibitors -- NEUROMUSCULAR BLOCKING AGENTS -- Depolarizing Muscle Nicotinic Receptor Neuromuscular Blocking Agents -- Non-depolarizing Muscle Nicotinic Receptor Neuromuscular Blocking Agents -- Ganglionic-Nicotinic Receptor Blocking Agents -- TREATMENT OF ALZHEIMER'S DISEASE (AD) -- Epidemiology -- Pathophysiology -- β-Amyloid Hypothesis -- Cholinergic Hypothesis -- Other Hypothesis -- Pharmacotherapy -- Acetyl Cholinesterase (AChE) Inhibitors | |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH38256597 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL6371154 | ||
| 938 | |a YBP Library Services |b YANK |n 301624536 | ||
| 938 | |a EBSCOhost |b EBSC |n 2649039 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-on1202480440 |
|---|---|
| _version_ | 1816882531918675968 |
| adam_text | |
| any_adam_object | |
| author2 | Faruk, M. O. Philip, Ashok E. |
| author2_role | |
| author2_variant | m o f mo mof a e p ae aep |
| author_facet | Faruk, M. O. Philip, Ashok E. |
| author_sort | Faruk, M. O. |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RM315 |
| callnumber-raw | RM315 |
| callnumber-search | RM315 |
| callnumber-sort | RM 3315 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| collection | ZDB-4-EBA |
| contents | Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- Drugs Affecting the Cholinergic System -- Cory R. Theberge1, Kim Lindsey-Goodrich2 and Ashok E. Philip3,* -- HISTORICAL PERSPECTIVES -- INTRODUCTORY CONCEPTS -- Choline and Acetylcholine -- Acetylcholine and Neurotransmission -- Cholinergic Neurochemistry: ACh Biosynthesis, Storage, Release, and Metabolism -- Cholinergic Receptors -- Muscarinic and Nicotinic Subtypes -- Clinical Use of Acetylcholine -- MUSCARINIC RECEPTOR AGONISTS -- MUSCARINIC RECEPTOR ANTAGONISTS (ANTICHOLINERGICS) Donepezil (Aricept®) -- Pharmacokinetics -- Side effects/Drug Interactions -- Rivastigmine (Exelon®) 2000, Oral -- 2008, Patch -- Pharmacokinetics -- Side effects/Drug Interactions -- Galantamine (Razadyne®) 2001 -- Pharmacokinetics -- Side effects/Drug-interactions -- NMDA Receptor Antagonist: Memantine (Namenda®) 2003 -- Pharmacokinetics -- Side effects/Drug interactions -- Place in Therapy -- CASE STUDY -- What therapeutic modifications would you make at this time and why? -- Drug Discovery Case Study -- The Quaternary Advantage -- Ipratropium and the Kinetic Selectivity of Tiotropium STUDENT SELF STUDY GUIDE -- PRACTICE QUESTIONS -- NOTES -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Drugs Affecting Adrenergic System -- M. O. Faruk1,* and Les Ramos2 -- HISTORICAL BACKGROUND -- THE INTRODUCTORY CONCEPTS -- Adrenergic Neurotransmitters -- Adrenergic Receptors (ARs) -- DRUGS AFFECTING ADRENERGIC SYSTEM: STRUCTURES, ACTIVITY, METABOLISM AND RELATED THERAPEUTIC CONSIDERATIONS -- The Antiadrenergics Affecting Synthesis, Storage, or Release of NE (Fig. 7) -- Metyrosine -- Reserpine -- Mechanism of Action -- Pharmacokinetics |
| ctrlnum | (OCoLC)1202480440 |
| dewey-full | 615.78 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.78 |
| dewey-search | 615.78 |
| dewey-sort | 3615.78 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>06331cam a2200637Mu 4500</leader><controlfield tag="001">ZDB-4-EBA-on1202480440</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cnu---unuuu</controlfield><controlfield tag="008">201031s2020 si o ||| 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">EBLCP</subfield><subfield code="b">eng</subfield><subfield code="c">EBLCP</subfield><subfield code="d">EBLCP</subfield><subfield code="d">YDX</subfield><subfield code="d">UKAHL</subfield><subfield code="d">N$T</subfield><subfield code="d">OCLCF</subfield><subfield code="d">OCLCO</subfield><subfield code="d">K6U</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield></datafield><datafield tag="066" ind1=" " ind2=" "><subfield code="c">(S</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">1200197704</subfield><subfield code="a">1202449622</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9811454078</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9789811454073</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1202480440</subfield><subfield code="z">(OCoLC)1200197704</subfield><subfield code="z">(OCoLC)1202449622</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RM315</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">615.78</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Medicinal Chemistry of Drugs Affecting the Nervous System</subfield><subfield code="h">[electronic resource].</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Singapore :</subfield><subfield code="b">Bentham Science Publishers,</subfield><subfield code="c">2020.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (406 p.).</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Medicinal Chemistry for Pharmacy Students Ser.</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Description based upon print version of record.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- Drugs Affecting the Cholinergic System -- Cory R. Theberge1, Kim Lindsey-Goodrich2 and Ashok E. Philip3,* -- HISTORICAL PERSPECTIVES -- INTRODUCTORY CONCEPTS -- Choline and Acetylcholine -- Acetylcholine and Neurotransmission -- Cholinergic Neurochemistry: ACh Biosynthesis, Storage, Release, and Metabolism -- Cholinergic Receptors -- Muscarinic and Nicotinic Subtypes -- Clinical Use of Acetylcholine -- MUSCARINIC RECEPTOR AGONISTS -- MUSCARINIC RECEPTOR ANTAGONISTS (ANTICHOLINERGICS)</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Donepezil (Aricept®) -- Pharmacokinetics -- Side effects/Drug Interactions -- Rivastigmine (Exelon®) 2000, Oral -- 2008, Patch -- Pharmacokinetics -- Side effects/Drug Interactions -- Galantamine (Razadyne®) 2001 -- Pharmacokinetics -- Side effects/Drug-interactions -- NMDA Receptor Antagonist: Memantine (Namenda®) 2003 -- Pharmacokinetics -- Side effects/Drug interactions -- Place in Therapy -- CASE STUDY -- What therapeutic modifications would you make at this time and why? -- Drug Discovery Case Study -- The Quaternary Advantage -- Ipratropium and the Kinetic Selectivity of Tiotropium</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">STUDENT SELF STUDY GUIDE -- PRACTICE QUESTIONS -- NOTES -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Drugs Affecting Adrenergic System -- M. O. Faruk1,* and Les Ramos2 -- HISTORICAL BACKGROUND -- THE INTRODUCTORY CONCEPTS -- Adrenergic Neurotransmitters -- Adrenergic Receptors (ARs) -- DRUGS AFFECTING ADRENERGIC SYSTEM: STRUCTURES, ACTIVITY, METABOLISM AND RELATED THERAPEUTIC CONSIDERATIONS -- The Antiadrenergics Affecting Synthesis, Storage, or Release of NE (Fig. 7) -- Metyrosine -- Reserpine -- Mechanism of Action -- Pharmacokinetics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The primary objective of this 4-volume book series is to educate PharmD students on the subject of medicinal chemistry. The book set serves as a reference guide to pharmacists on aspects of the chemical basis of drug action. Medicinal Chemistry of Drugs Affecting the Nervous System is the second volume of the series and it presents 8 chapters focusing on a comprehensive account of drugs affecting the nervous system. The volume informs readers about the medicinal chemistry of relevant drugs, which includes the mechanism of drug action, detail structure activity relationships and metabolism as w.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Neuropharmacology.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85091157</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Autonomic nervous system</subfield><subfield code="x">Effect of drugs on.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Central nervous system</subfield><subfield code="x">Effect of drugs on.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmaceutical chemistry.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85023026</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Neuropharmacology</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D009480</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Chemistry, Pharmaceutical</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D002626</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Neuropharmacologie.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Système nerveux autonome</subfield><subfield code="x">Effets des médicaments sur.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Système nerveux central</subfield><subfield code="x">Effets des médicaments sur.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Chimie pharmaceutique.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Central nervous system</subfield><subfield code="x">Effect of drugs on</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neuropharmacology</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical chemistry</subfield><subfield code="2">fast</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Faruk, M. O.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Philip, Ashok E.</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">Medicinal chemistry of drugs affecting the nervous system (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCYjJk8cCWMXTfpjt7C9KdP</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Faruk, M. O.</subfield><subfield code="t">Medicinal Chemistry of Drugs Affecting the Nervous System</subfield><subfield code="d">Singapore : Bentham Science Publishers,c2020</subfield><subfield code="z">9789811454059</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Medicinal Chemistry for Pharmacy Students Ser.</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2649039</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="880" ind1=" " ind2=" "><subfield code="6">500-00/(S</subfield><subfield code="a">Therapeutic Evaluation of the Imidazoline α Adrenergic Agonists</subfield></datafield><datafield tag="880" ind1="8" ind2=" "><subfield code="6">505-00/(S</subfield><subfield code="a">Guanethidine and Guanadrel -- Direct-Acting Sympathomimetic Agents -- The General Mechanism and SAR of β-Phenylethylamine Derivatives (Direct and Indirect Acting Agonists) -- Sar 1 -- Sar 2 -- Sar 3 -- Sar 4 -- Sar 5 -- Sar 6 -- Sar 7 -- Sar 8 -- Sar 9 -- Therapeutic Evaluation of the β-Phenylethylamine Direct Acting Adrenergic Agonists -- β2 Adrenergic Agonist and Cardiac Function -- Long Acting β2-Adrenoceptor Agonists (LABAs) -- β3 Adrenergic Receptor Agonist -- The General SAR of Imidazolines (α Adrenergic Agonist and Antagonists) -- Sar 1 -- Sar 2 -- Sar 3</subfield></datafield><datafield tag="880" ind1="8" ind2=" "><subfield code="6">505-00/(S</subfield><subfield code="a">Acetylcholinesterase (AChE) Inhibitors -- Reversible Noncovalent Inhibitors -- Reversible Covalent Inhibitors -- Irreversible Covalent Inhibitors -- NEUROMUSCULAR BLOCKING AGENTS -- Depolarizing Muscle Nicotinic Receptor Neuromuscular Blocking Agents -- Non-depolarizing Muscle Nicotinic Receptor Neuromuscular Blocking Agents -- Ganglionic-Nicotinic Receptor Blocking Agents -- TREATMENT OF ALZHEIMER'S DISEASE (AD) -- Epidemiology -- Pathophysiology -- β-Amyloid Hypothesis -- Cholinergic Hypothesis -- Other Hypothesis -- Pharmacotherapy -- Acetyl Cholinesterase (AChE) Inhibitors</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Askews and Holts Library Services</subfield><subfield code="b">ASKH</subfield><subfield code="n">AH38256597</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL6371154</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">301624536</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">2649039</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-on1202480440 |
| illustrated | Not Illustrated |
| indexdate | 2024-11-27T13:30:06Z |
| institution | BVB |
| isbn | 9811454078 9789811454073 |
| language | English |
| oclc_num | 1202480440 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (406 p.). |
| psigel | ZDB-4-EBA |
| publishDate | 2020 |
| publishDateSearch | 2020 |
| publishDateSort | 2020 |
| publisher | Bentham Science Publishers, |
| record_format | marc |
| series | Medicinal Chemistry for Pharmacy Students Ser. |
| series2 | Medicinal Chemistry for Pharmacy Students Ser. |
| spelling | Medicinal Chemistry of Drugs Affecting the Nervous System [electronic resource]. Singapore : Bentham Science Publishers, 2020. 1 online resource (406 p.). Medicinal Chemistry for Pharmacy Students Ser. Description based upon print version of record. Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- Drugs Affecting the Cholinergic System -- Cory R. Theberge1, Kim Lindsey-Goodrich2 and Ashok E. Philip3,* -- HISTORICAL PERSPECTIVES -- INTRODUCTORY CONCEPTS -- Choline and Acetylcholine -- Acetylcholine and Neurotransmission -- Cholinergic Neurochemistry: ACh Biosynthesis, Storage, Release, and Metabolism -- Cholinergic Receptors -- Muscarinic and Nicotinic Subtypes -- Clinical Use of Acetylcholine -- MUSCARINIC RECEPTOR AGONISTS -- MUSCARINIC RECEPTOR ANTAGONISTS (ANTICHOLINERGICS) Donepezil (Aricept®) -- Pharmacokinetics -- Side effects/Drug Interactions -- Rivastigmine (Exelon®) 2000, Oral -- 2008, Patch -- Pharmacokinetics -- Side effects/Drug Interactions -- Galantamine (Razadyne®) 2001 -- Pharmacokinetics -- Side effects/Drug-interactions -- NMDA Receptor Antagonist: Memantine (Namenda®) 2003 -- Pharmacokinetics -- Side effects/Drug interactions -- Place in Therapy -- CASE STUDY -- What therapeutic modifications would you make at this time and why? -- Drug Discovery Case Study -- The Quaternary Advantage -- Ipratropium and the Kinetic Selectivity of Tiotropium STUDENT SELF STUDY GUIDE -- PRACTICE QUESTIONS -- NOTES -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Drugs Affecting Adrenergic System -- M. O. Faruk1,* and Les Ramos2 -- HISTORICAL BACKGROUND -- THE INTRODUCTORY CONCEPTS -- Adrenergic Neurotransmitters -- Adrenergic Receptors (ARs) -- DRUGS AFFECTING ADRENERGIC SYSTEM: STRUCTURES, ACTIVITY, METABOLISM AND RELATED THERAPEUTIC CONSIDERATIONS -- The Antiadrenergics Affecting Synthesis, Storage, or Release of NE (Fig. 7) -- Metyrosine -- Reserpine -- Mechanism of Action -- Pharmacokinetics The primary objective of this 4-volume book series is to educate PharmD students on the subject of medicinal chemistry. The book set serves as a reference guide to pharmacists on aspects of the chemical basis of drug action. Medicinal Chemistry of Drugs Affecting the Nervous System is the second volume of the series and it presents 8 chapters focusing on a comprehensive account of drugs affecting the nervous system. The volume informs readers about the medicinal chemistry of relevant drugs, which includes the mechanism of drug action, detail structure activity relationships and metabolism as w. Neuropharmacology. http://id.loc.gov/authorities/subjects/sh85091157 Autonomic nervous system Effect of drugs on. Central nervous system Effect of drugs on. Pharmaceutical chemistry. http://id.loc.gov/authorities/subjects/sh85023026 Neuropharmacology https://id.nlm.nih.gov/mesh/D009480 Chemistry, Pharmaceutical https://id.nlm.nih.gov/mesh/D002626 Neuropharmacologie. Système nerveux autonome Effets des médicaments sur. Système nerveux central Effets des médicaments sur. Chimie pharmaceutique. Central nervous system Effect of drugs on fast Neuropharmacology fast Pharmaceutical chemistry fast Faruk, M. O. Philip, Ashok E. has work: Medicinal chemistry of drugs affecting the nervous system (Text) https://id.oclc.org/worldcat/entity/E39PCYjJk8cCWMXTfpjt7C9KdP https://id.oclc.org/worldcat/ontology/hasWork Print version: Faruk, M. O. Medicinal Chemistry of Drugs Affecting the Nervous System Singapore : Bentham Science Publishers,c2020 9789811454059 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2649039 Volltext 500-00/(S Therapeutic Evaluation of the Imidazoline α Adrenergic Agonists 505-00/(S Guanethidine and Guanadrel -- Direct-Acting Sympathomimetic Agents -- The General Mechanism and SAR of β-Phenylethylamine Derivatives (Direct and Indirect Acting Agonists) -- Sar 1 -- Sar 2 -- Sar 3 -- Sar 4 -- Sar 5 -- Sar 6 -- Sar 7 -- Sar 8 -- Sar 9 -- Therapeutic Evaluation of the β-Phenylethylamine Direct Acting Adrenergic Agonists -- β2 Adrenergic Agonist and Cardiac Function -- Long Acting β2-Adrenoceptor Agonists (LABAs) -- β3 Adrenergic Receptor Agonist -- The General SAR of Imidazolines (α Adrenergic Agonist and Antagonists) -- Sar 1 -- Sar 2 -- Sar 3 505-00/(S Acetylcholinesterase (AChE) Inhibitors -- Reversible Noncovalent Inhibitors -- Reversible Covalent Inhibitors -- Irreversible Covalent Inhibitors -- NEUROMUSCULAR BLOCKING AGENTS -- Depolarizing Muscle Nicotinic Receptor Neuromuscular Blocking Agents -- Non-depolarizing Muscle Nicotinic Receptor Neuromuscular Blocking Agents -- Ganglionic-Nicotinic Receptor Blocking Agents -- TREATMENT OF ALZHEIMER'S DISEASE (AD) -- Epidemiology -- Pathophysiology -- β-Amyloid Hypothesis -- Cholinergic Hypothesis -- Other Hypothesis -- Pharmacotherapy -- Acetyl Cholinesterase (AChE) Inhibitors |
| spellingShingle | Medicinal Chemistry of Drugs Affecting the Nervous System Medicinal Chemistry for Pharmacy Students Ser. Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- Drugs Affecting the Cholinergic System -- Cory R. Theberge1, Kim Lindsey-Goodrich2 and Ashok E. Philip3,* -- HISTORICAL PERSPECTIVES -- INTRODUCTORY CONCEPTS -- Choline and Acetylcholine -- Acetylcholine and Neurotransmission -- Cholinergic Neurochemistry: ACh Biosynthesis, Storage, Release, and Metabolism -- Cholinergic Receptors -- Muscarinic and Nicotinic Subtypes -- Clinical Use of Acetylcholine -- MUSCARINIC RECEPTOR AGONISTS -- MUSCARINIC RECEPTOR ANTAGONISTS (ANTICHOLINERGICS) Donepezil (Aricept®) -- Pharmacokinetics -- Side effects/Drug Interactions -- Rivastigmine (Exelon®) 2000, Oral -- 2008, Patch -- Pharmacokinetics -- Side effects/Drug Interactions -- Galantamine (Razadyne®) 2001 -- Pharmacokinetics -- Side effects/Drug-interactions -- NMDA Receptor Antagonist: Memantine (Namenda®) 2003 -- Pharmacokinetics -- Side effects/Drug interactions -- Place in Therapy -- CASE STUDY -- What therapeutic modifications would you make at this time and why? -- Drug Discovery Case Study -- The Quaternary Advantage -- Ipratropium and the Kinetic Selectivity of Tiotropium STUDENT SELF STUDY GUIDE -- PRACTICE QUESTIONS -- NOTES -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Drugs Affecting Adrenergic System -- M. O. Faruk1,* and Les Ramos2 -- HISTORICAL BACKGROUND -- THE INTRODUCTORY CONCEPTS -- Adrenergic Neurotransmitters -- Adrenergic Receptors (ARs) -- DRUGS AFFECTING ADRENERGIC SYSTEM: STRUCTURES, ACTIVITY, METABOLISM AND RELATED THERAPEUTIC CONSIDERATIONS -- The Antiadrenergics Affecting Synthesis, Storage, or Release of NE (Fig. 7) -- Metyrosine -- Reserpine -- Mechanism of Action -- Pharmacokinetics Neuropharmacology. http://id.loc.gov/authorities/subjects/sh85091157 Autonomic nervous system Effect of drugs on. Central nervous system Effect of drugs on. Pharmaceutical chemistry. http://id.loc.gov/authorities/subjects/sh85023026 Neuropharmacology https://id.nlm.nih.gov/mesh/D009480 Chemistry, Pharmaceutical https://id.nlm.nih.gov/mesh/D002626 Neuropharmacologie. Système nerveux autonome Effets des médicaments sur. Système nerveux central Effets des médicaments sur. Chimie pharmaceutique. Central nervous system Effect of drugs on fast Neuropharmacology fast Pharmaceutical chemistry fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh85091157 http://id.loc.gov/authorities/subjects/sh85023026 https://id.nlm.nih.gov/mesh/D009480 https://id.nlm.nih.gov/mesh/D002626 |
| title | Medicinal Chemistry of Drugs Affecting the Nervous System |
| title_auth | Medicinal Chemistry of Drugs Affecting the Nervous System |
| title_exact_search | Medicinal Chemistry of Drugs Affecting the Nervous System |
| title_full | Medicinal Chemistry of Drugs Affecting the Nervous System [electronic resource]. |
| title_fullStr | Medicinal Chemistry of Drugs Affecting the Nervous System [electronic resource]. |
| title_full_unstemmed | Medicinal Chemistry of Drugs Affecting the Nervous System [electronic resource]. |
| title_short | Medicinal Chemistry of Drugs Affecting the Nervous System |
| title_sort | medicinal chemistry of drugs affecting the nervous system |
| topic | Neuropharmacology. http://id.loc.gov/authorities/subjects/sh85091157 Autonomic nervous system Effect of drugs on. Central nervous system Effect of drugs on. Pharmaceutical chemistry. http://id.loc.gov/authorities/subjects/sh85023026 Neuropharmacology https://id.nlm.nih.gov/mesh/D009480 Chemistry, Pharmaceutical https://id.nlm.nih.gov/mesh/D002626 Neuropharmacologie. Système nerveux autonome Effets des médicaments sur. Système nerveux central Effets des médicaments sur. Chimie pharmaceutique. Central nervous system Effect of drugs on fast Neuropharmacology fast Pharmaceutical chemistry fast |
| topic_facet | Neuropharmacology. Autonomic nervous system Effect of drugs on. Central nervous system Effect of drugs on. Pharmaceutical chemistry. Neuropharmacology Chemistry, Pharmaceutical Neuropharmacologie. Système nerveux autonome Effets des médicaments sur. Système nerveux central Effets des médicaments sur. Chimie pharmaceutique. Central nervous system Effect of drugs on Pharmaceutical chemistry |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2649039 |
| work_keys_str_mv | AT farukmo medicinalchemistryofdrugsaffectingthenervoussystem AT philipashoke medicinalchemistryofdrugsaffectingthenervoussystem |